Matinas BioPharma Holdings, Inc. announced its leadership succession plan, with the Board of Directors unanimously appointing current board member, Eric J. Ende, to succeed Herbert J. Conrad as Chairman of the Board. Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company. The succession will be effective October 1, 2022.

Dr. Ende joined the Company's Board of Directors in March 2017. Dr. Ende was a director on Genzyme's Board from 2010 – 2011 until it was acquired by Sanofi-Aventis for $21B in 2011. Dr. Ende is currently on the Board of Directors of Avadel plc, where he is the Chairman of the Nomination & Corporate Governance Committee and is serving on the Audit Committee.

Dr. Ende is also on the Technology Transfer Committee of Mount Sinai Innovation Partners. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. During Dr. Ende's career as a biotechnology analyst, he was named to Institutional Investor's All-America Equity Research Team six times as well as to The Greenwich Survey list of top analysts.

He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com. Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School, an MD from Mount Sinai School of Medicine, and a BS in Biology and Psychology from Emory University.